Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers’ diarrhea

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers’ diarrhea
Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers’ diarrhea.

Read more on News-Medical-Net